title: Chemotherapy-induced oral mucositis: new approaches to prevention and management.
abstract: Oral mucositis is a common and significant toxicity of cancer chemotherapy. It is under-reported and not well treated, particularly in patients that receive high-dose therapy with an autologous or allogenic stem cell transplant. Two recently published retrospective analyses of patient complaints following stem cell transplantation have identified oral mucositis as the worst toxicity reported by patients, and what is more important is that patients indicated that oncology healthcare team members do a poor job of managing and providing methods of symptom relief. Twenty percent of patients surveyed indicated they received no symptom relief at all.
authors.affiliation: Princess Margaret Hospital, Department of Medical Oncology, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.
authors.forename: Janice
authors.initials: J
authors.lastname: Wright
authors.forename: Ronald
authors.initials: R
authors.lastname: Feld
authors.forename: Jennifer
authors.initials: J
authors.lastname: Knox
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001591:Benzydamine / Q000627:therapeutic use; D017679:Cryotherapy; D051523:Fibroblast Growth Factor 7 / Q000627:therapeutic use; D005973:Glutamine / Q000627:therapeutic use; D006801:Humans; D011788:Quality of Life; D012307:Risk Factors; D013280:Stomatitis / Q000139:chemically induced* / Q000145:classification / Q000517:prevention & control*
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D005973:Glutamine; D051523:Fibroblast Growth Factor 7; D001591:Benzydamine